Showing results (61-70 of 296) with videos related to
Sort By:
Pageof 30
BJU International|April 24, 2012
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapyGregory R Pond, Andrew J Armstrong, Brian A Wood, et al.Clinical Genitourinary Cancer|October 9, 2012
Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitorsJames D Turnbull, Julien Cobert, Tracy Jaffe, et al.Urologic Oncology|May 4, 2012
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trialsGregory R Pond, Andrew J Armstrong, Matthew D Galsky, et al.European Journal of Cancer (Oxford, England : 1990)|December 17, 2009
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survivalAndrew J Armstrong, Ian F Tannock, Ronald de Wit, et al.Biorxiv : the Preprint Server for Biology|November 24, 2025
A memory-driven reinforcement learning model of phenotypic adaptation for anticipating therapeutic resistance in prostate cancerZahra S Ghoreyshi, Shibjyoti Debnath, Pelumi D Olawuni, et al.European Urology|October 15, 2013
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancerGregory R Pond, Guru Sonpavde, Ronald de Wit, et al.Translational Vision Science & Technology|February 10, 2018
The Effects of Glaucoma Drainage Devices on Oxygen Tension, Glycolytic Metabolites, and Metabolomics Profile of Aqueous Humor in the RabbitBlake K Williamson, Nathan M Hawkey, Diane A Blake, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|October 22, 2016
Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndromeSundhar Ramalingam, Adva Eisenberg, Wen Chi Foo, et al.Journal for Immunotherapy of Cancer|January 26, 2018
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyondJason Zhu, Andrew J Armstrong, Terence W Friedlander, et al.Future Oncology (London, England)|July 14, 2025
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPCAndrew J Armstrong, Bhavik J Pandya, Hemant Singh Bhadauria, et al.Pageof 30